<i>Ex vivo</i> analysis shows the infiltration of CD8+ T cells to brain and glioma.

<p>Panel <b>A</b> shows IHC of fluorescently labeled Pmel-1 CD8+ T cells. Animals were infused with T cells (2×10⁷) and sacrificed for IHC staining two days after cell infusion. Sparse T cells are shown at the arrows. Panels <b>B–C</b> show quantitative flow cytometry of Pmel-1, hgp100-specific T cells in brain cell suspension with CD8+ (<b>B</b>) and CD3+ (<b>C</b>) gating. Panel <b>D</b> shows quantitative flow cytometry of wild-type T cells. Here, PE = Phycoerythrin, FITC = Fluorescein isothiocyanate, and TIL = tumor infiltrating lymphocytes.</p

<i>In vivo</i>¹⁹F/¹H MRI of mouse glioma showing ¹⁹F labeled tumor cells.

<p>Panel (<b>A</b>) is a ¹H axial image and panel (<b>B</b>) is a composite ¹⁹F and ¹H image of PCE labeled GL261 glioma cells in the right striatum at day 5 post tumor inoculation. The ¹⁹F image is rendered in a hot-iron intensity scale, and the ¹H is in gray scale. Unlabeled GL261 cells were injected into the contralateral striatum in the same imaging plane. Diluted PCE emulsion (9.8 mg/ml) in 2% agarose was used as a ¹⁹F reference (shown at bottom).</p

<i>In vivo</i> longitudinal pO₂ changes of CNS GL261 tumor.

<p>Panel (<b>A</b>) shows the pO₂ (left axis) and R₁ (right axis) values. Panel (<b>B</b>) displays the total normalized ¹⁹F signal of the tumor over time. On day 3, Pmel-1 antigen-specific CD8+ T cells or wild-type T cells were injected into the corresponding groups, and the control group received no cells. Here, (*) denotes p<0.05 comparing Pmel-1 group with wild-type T cell and no-cell groups.</p

<i>In vitro</i> calibration curve for R₁ = 1/T₁ versus pO₂.

<p>Here, solid circles represent average ¹⁹F R₁ measurements of six oxygen partial pressure values, each in triplicate, ranging from 0% to 100% oxygen in a saturated O₂/N₂ mixture of PFC emulsion in water. The solid line is the calibration curve fit by the linear least squares method (R² = 0.99). Data were collected at 11.7 T and 37°C. 100% oxygen is equivalent to 760 mm Hg. (The R₁ error bars are smaller than the point size.)</p

Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma-4

<p><b>Copyright information:</b></p><p>Taken from "Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma"</p><p>http://www.translational-medicine.com/content/5/1/68</p><p>Journal of Translational Medicine 2007;5():68-68.</p><p>Published online 19 Dec 2007</p><p>PMCID:PMC2244605.</p><p></p>08 mIgG1) (), or without primary antibody () as described in Materials and Methods. Original magnification was × 20

Additional file 1: of The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion

Table S1. Cell populations analyzed in tumor tissues of glioma patients. Supplementary materials and methods. Description of patient characteristics, multiparametric flow cytometry, functional assay, t-SNE analysis and experiments with nanoparticles. (DOCX 22 kb

De Waarheid. Volksdag-blad ["puis" Volkstageblad] voor bevrigd Nederland

novembre 19441944/11-1945/02

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas-0

<p><b>Copyright information:</b></p><p>Taken from "Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas"</p><p>http://www.translational-medicine.com/content/5/1/67</p><p>Journal of Translational Medicine 2007;5():67-67.</p><p>Published online 19 Dec 2007</p><p>PMCID:PMC2254376.</p><p></p>that were not stimulated with the type-1 cytokine-mixture (standard DCs). This was done with 24 hr stimulation of DCs (20 × 10per well, duplicates) with CD40L-transfected J558 cells (50 × 10per well). Supernatant was harvested and the production of IL-12 p70 was assayed by specific ELISA. Values indicate averages of duplicate samples. Bars indicate standard errors

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas-2

<p><b>Copyright information:</b></p><p>Taken from "Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas"</p><p>http://www.translational-medicine.com/content/5/1/67</p><p>Journal of Translational Medicine 2007;5():67-67.</p><p>Published online 19 Dec 2007</p><p>PMCID:PMC2254376.</p><p></p> by a neuroradiologist

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas-1

<p><b>Copyright information:</b></p><p>Taken from "Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas"</p><p>http://www.translational-medicine.com/content/5/1/67</p><p>Journal of Translational Medicine 2007;5():67-67.</p><p>Published online 19 Dec 2007</p><p>PMCID:PMC2254376.</p><p></p>aved as frozen cells until all these cells were thawed at the same time, cultured in the presence of 20 IU/ml hIL-2 and autologous glioma cells for 5 days, and evaluated for the frequency of IFN-γ-producing cells in response to T2 cells loaded with the HLA-A2-binding EphA2peptide using ELISPOT assay. Each well contained 5 × 10CD8cells and each group was evaluated in triplicate. Specific IFN-γ spots were calculated by subtracting the average of control spots (triplicate variation within a group was less than 10% in non-peptide-loaded T2 cell groups) from the total numbers of spots in peptide-loaded groups. Values indicate averages of triplicate samples for each time point, and bars indicate standard deviations. The number of spots in each post-vaccine time point was at least three times the standard-deviation of the pre-vaccine value